Physician profile
Qing Ge
NPI 1225053192
$1,326.40
in general payments reported to CMS, 2019-2025
20 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $106 · 2021: $192 · 2022: $160 · 2023: $154 · 2024: $163 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $198.50 | 2019-2022 | |
| Biotissue Holdings INC. | $198.32 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $159.87 | 2021-2025 | |
| Harrow Eye, LLC | $122.09 | 2024-2025 | Vevye |
| Abbvie INC. | $84.66 | 2022-2024 | |
| Glaukos Corporation | $64.14 | 2023-2025 | Istent Infinite |
| Bausch & Lomb Americas INC. | $63.34 | 2023-2024 | Envista Mx60 Iol, Zylet, Prolensa |
| Alcon Vision LLC | $58.33 | 2022-2025 | Eysuvis |
| Allergan, INC. | $55.54 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $53.99 | 2019 | |
| Dompe US, INC. | $45.24 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.02 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $38.69 | 2025 | Xdemvy |
| Sight Sciences, INC. | $24.61 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.11 | 2023 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $22.26 | 2021 | |
| Rayner Intraocular Lenses Limited | $20.52 | 2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $20.21 | 2021 | |
| Omeros Corporation | $16.00 | 2019 | |
| Shire North American Group INC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Ge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.